XML 15 R4.htm IDEA: XBRL DOCUMENT v3.25.1
CONDENSED CONSOLIDATED BALANCE SHEET - USD ($)
$ in Millions
Mar. 31, 2025
Dec. 31, 2024
Current Assets    
Cash and cash equivalents $ 8,629 $ 13,242
Short-term investments 599 447
Accounts receivable (net of allowance for doubtful accounts of $93 in 2025 and $89 in 2024) 10,790 10,278
Inventories (excludes inventories of $4,556 in 2025 and $4,193 in 2024 classified in Other assets - see Note 6) 6,196 6,109
Other current assets 9,289 8,706
Total current assets 35,503 38,782
Investments 616 463
Property, Plant and Equipment, at cost, net of accumulated depreciation of $19,680 in 2025 and $19,155 in 2024 24,793 23,779
Goodwill 21,684 21,668
Other Intangibles, Net 15,758 16,370
Other Assets 16,768 16,044
Total Assets 115,122 117,106
Current Liabilities    
Loans payable and current portion of long-term debt 1,360 2,649
Trade accounts payable 3,784 4,079
Accrued and other current liabilities 12,772 15,694
Income taxes payable 5,181 3,914
Dividends payable 2,077 2,084
Total current liabilities 25,174 28,420
Long-Term Debt 33,484 34,462
Deferred Income Taxes 1,409 1,387
Other Noncurrent Liabilities 6,655 6,465
Merck & Co., Inc. Stockholders’ Equity    
Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2025 and 2024 1,788 1,788
Other paid-in capital 44,816 44,704
Retained earnings 66,097 63,069
Accumulated other comprehensive loss (4,965) (4,945)
Stockholders' equity before deduction for treasury stock 107,736 104,616
Less treasury stock, at cost: 1,061,021,894 shares in 2025 and 1,049,466,187 shares in 2024 59,401 58,303
Total Merck & Co., Inc. stockholders’ equity 48,335 46,313
Noncontrolling Interests 65 59
Total equity 48,400 46,372
Liabilities and Equity $ 115,122 $ 117,106